Unlike the majority of biotech players, Kazia Therapeutics has emphasised diversity in its clinical trials, so as to look at the potential of its lead drug paxalisib in a range of different treatment areas.

Kazia Therapeutics CEO James Garner joins Small Caps to discuss the company’s ongoing development of its lead drug paxalisib, which recently generated positive interim data in a phase one clinical trial for treating brain metastases.

Interim data from the study reveals a complete or partial response in all evaluable trial participants for a disease with a poor prognosis and limited current options.

Kazia has launched a new Scientific Advisory Board (SAB) consisting of four distinguished clinicians and scientists with expertise in the development of innovative therapies for brain cancer.

Kazia has been awarded a Rare Paediatric Disease Designation (RPDD) by the US Food and Drug Administration (FDA) for the use of paxalisib in the treatment of atypical rhabdoid/teratoid tumours (AT/RT), a rare and highly aggressive childhood brain cancer.

The US FDA has awarded Kazia Therapeutics (ASX:KZA) a designation for its treatment for rare brain cancer in children. 

Kazia is making good progress with its two pipeline assets, paxalisib and EVT801, with the latter having cleared third dose level and is recruiting well.

The company also notes the GBM AGILE pivotal study has opened in France, the fourth country to start recruitment to the paxalisib arm.

“Positive data” is being presented regarding the activity of Kazia's lead drug paxalisib in two forms of childhood brain cancers.

The company is presenting the data via two presentations this week at the 20^th International Symposium on Pediatric Neuro-Oncology (ISPNO) in Germany.

Dr James Garner provides an update on the oncology company's lead program, a glioblastoma treatment candidate known as paxalisib.

Kazia Therapeutics has announced that the GBM AGILE study in glioblastoma has opened recruitment to the paxalisib arm in Europe.

Kazia Therapeutics marks 'DIPG Awareness Day' by recognizing the tireless work of global researchers in this disease, and by calling for an increased focus on childhood brain cancer among policymakers.

Kazia CEO Dr James Garner tells Andrew Scott about the company's quarterly achievements, including data the company presented at the American Association of Cancer Research (AACR) conference on the use of its asset paxalisib in a rare, aggressive childhood cancer. It has been a busy quarter for the company on the trials front, and news for investors is good too, with the company introducing an at-the-market financing facility in the US - a quick and efficient way of transacting on biotech shares.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of a poster presentation at the upcoming Annual Meeting of the American Society for Clinical Oncology (ASCO).

Kazia Therapeutics (ASX: KZA)has recruited its first patient into a Phase II study of investigational new drug paxalisib for the treatment of newly-diagnosed and recurrent glioblastoma.

Oncology-focused and clinical stage biotechnology company Kazia Therapeutics (ASX: KZA) has reported strong progress on the development of its lead drug candidates during the three months to 31 December.

Kazia Therapeutics Limited will be presenting at the BIO CEO Conference, to be held in person and virtually in New York, NY, from 14-17 February 2022. Kazia will be presenting in person on day one of the conference, Monday, 14 February. The presentation will provide an update on recent progress with Kazia's two clinical-stage oncology programs and will cover some of the important catalysts expected during 2022

In this role, Ms Krumeich will focus on building and maintaining relationships with US investors, on preparing the company for future expansion, and on raising the profile of Kazia in global markets. Ms Krumeich is based in Pennsylvania in the United States and will formally commence work with Kazia in January 2022.

The study tested paxalisib's effectiveness in patients whose genetic profile confers resistance to the only other treatment available for this condition. Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA), a cancer-focused drug development company based in Sydney, has released final data from its Phase 2 clinical study of the drug paxalisib – a first-line therapy in patients with glioblastoma.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The results confirm the previously reported safety and efficacy profile with paxalisib in this high unmet need disease.